© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli arrives at U.S. District Court for the third day of jury deliberations in his securities fraud trial in the Brooklyn borough of New York City, U.S., August 2, 2017. REUTERS/Amr Alfiky
WASHINGTON (Reuters) – The U.S. Federal Trade Commission has reached a settlement agreement with Vyera Pharmaceuticals over allegations it sought to block generic versions of its drug Daraprim, they said in a court filing.
Litigation against Martin Shkreli will continue, the filing said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment